Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a next-generation, small-molecule multi-target tyrosine kinase inhibitor (TKI) that potently inhibits VEGFR2 (IC₅₀: 5.6 ± 1.2 nM), PDGFRβ (IC₅₀: 8.7 ± 3.4 nM), and FGFR1 (IC₅₀: 11.7 ± 4.1 nM), with superior anti-angiogenic activity relative to sunitinib and sorafenib [Chen & Feng, 2019]. It demonstrates high oral bioavailability (28–77% in animals), extensive tissue distribution, and high plasma protein binding (93% in humans) [APExBIO]. Safety profiles show a high LD₅₀ (1735.9 mg/kg, 14-day oral, rats), with low organ and genetic toxicity in preclinical studies. Anlotinib enables robust inhibition of VEGF/PDGF-BB/FGF-2-induced endothelial migration and capillary tube formation in cell-based assays, and is a research-only reagent supplied by APExBIO.

Biological Rationale

Angiogenesis, the formation of new blood vessels, is a fundamental process in tumor growth and metastasis. Tumor vascularization is primarily regulated by growth factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF), each acting through specific receptor tyrosine kinases (RTKs) including VEGFR, PDGFR, and FGFR families. Inhibiting these signaling pathways disrupts tumor blood supply, starving cancer cells of nutrients and oxygen [Chen & Feng, 2019]. Conventional anti-angiogenic agents often target a single RTK, leading to adaptive resistance. Multi-targeted TKIs, such as anlotinib hydrochloride, address this limitation by simultaneously blocking multiple angiogenic signals [Anti-Trop2], offering enhanced efficacy in preclinical and translational cancer models.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a small-molecule inhibitor that selectively blocks the kinase activity of VEGFR2, PDGFRβ, and FGFR1. By binding to the ATP pocket of these RTKs, anlotinib prevents autophosphorylation and downstream signaling, notably the ERK pathway, which is critical for endothelial cell proliferation, migration, and survival. In cellular assays, anlotinib inhibits VEGF-, PDGF-BB-, and FGF-2-induced endothelial cell migration and capillary-like tube formation in a concentration-dependent manner [APExBIO]. The IC₅₀ values for inhibition are 5.6 ± 1.2 nM (VEGFR2), 8.7 ± 3.4 nM (PDGFRβ), and 11.7 ± 4.1 nM (FGFR1) at 37°C, pH 7.4, in optimized in vitro conditions. Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates superior potency and spectrum against these targets [ClothiapineApis]. Anlotinib also inhibits ERK phosphorylation, further suppressing angiogenic and tumorigenic signaling.

Evidence & Benchmarks

• Anlotinib demonstrated objective reduction of metastatic lymph node size in a clinical case of intra-abdominal desmoplastic small round cell tumor (IADSRCT) after four cycles, with manageable toxicity (Chen & Feng 2019, DOI:10.2147/OTT.S190333).
• In vitro, anlotinib inhibits VEGFR2 kinase activity with an IC₅₀ of 5.6 ± 1.2 nM, outperforming sunitinib and sorafenib under identical assay conditions (APExBIO datasheet, product page).
• Pharmacokinetic studies in rats and dogs show rapid oral absorption and bioavailability of 28–77%, with extensive tissue distribution including tumor, lung, liver, and kidney (APExBIO datasheet, product page).
• Cellular assays using EA.hy 926 human vascular endothelial cells confirm concentration-dependent inhibition of endothelial migration and tube formation (ClothiapineApis article, link).
• Preclinical safety data report a median lethal dose (LD₅₀) of 1735.9 mg/kg in 14-day oral studies in rats, with low systemic and genetic toxicity (APExBIO datasheet, product page).

This article clarifies the comparative anti-angiogenic benchmarks of Anlotinib versus legacy TKIs, extending the mechanistic focus of this Anti-Trop2 review by providing quantitative and workflow-specific insights.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is recommended exclusively for research use, particularly in cancer biology, angiogenesis, and tyrosine kinase signaling pathway studies. It is widely applied in:

• Endothelial cell migration and capillary tube formation assays
• Phosphorylation and signaling pathway analyses (e.g., ERK, Akt)
• Comparative studies of multi-target TKIs in tumor models
• Preclinical pharmacokinetics and tissue distribution studies

For practical experimental guidance and troubleshooting, see this workflow article, which highlights how APExBIO’s formulation ensures batch-to-batch consistency—an aspect only briefly mentioned in the present review.

Common Pitfalls or Misconceptions

• Not for clinical or diagnostic use: Anlotinib (hydrochloride) C8688 is for scientific research only; clinical administration outside approved studies is prohibited.
• Single-pathway inhibition is insufficient: The compound’s efficacy relies on multi-target inhibition; using it as a single-pathway blocker underestimates its potential.
• Cell line variability: Response profiles may differ across cell types and species; always validate in the relevant model system.
• Metabolic stability considerations: CYP3A-mediated metabolism can affect assay outcomes; include metabolic controls where relevant.
• Solubility and handling errors: Improper storage or solvent selection can reduce potency; follow APExBIO's storage (-20°C) and handling recommendations.

Workflow Integration & Parameters

For optimal research outcomes, Anlotinib (hydrochloride) C8688 from APExBIO should be stored at -20°C in a desiccated environment. Prepare stock solutions in DMSO, ensuring full solubilization before dilution in assay buffers. Use concentrations between 1–100 nM for endothelial cell assays, adjusting based on cell type and desired endpoint. For kinase inhibition studies, pre-incubate with the compound for 30–60 minutes at 37°C. Include negative (vehicle) and positive (e.g., sunitinib) controls for benchmarking. Monitor for cytotoxicity and adjust dosing to preserve cell viability where required.

The Anlotinib (hydrochloride) product page provides full technical data, including molecular weight, chemical structure, and batch-specific COAs. For expanded mechanistic workflows, see this Prescission article, which discusses strategic assay integration beyond standard endpoints covered here.

Conclusion & Outlook

Anlotinib hydrochloride is a validated, research-grade inhibitor of VEGFR2, PDGFRβ, and FGFR1, supporting advanced studies in tumor angiogenesis and tyrosine kinase signaling. Its superior potency, favorable PK profile, and robust safety record distinguish it from older TKIs in bench-to-bedside research. Ongoing studies are expanding its utility in resistance models and combination therapies. Researchers should leverage APExBIO’s high-purity C8688 formulation for reproducible, translationally relevant results in cancer research workflows.